CLINICAL_TRIALS ClinicalTrials.gov record update

Adjuvant Therapy for High-Risk Localized Breast Cancer Using Weekly Adriamycin + Daily Oral Cytoxan With Continuous G-CSF Support for 12 Weeks Followed by Weekly Abraxane™ for 12 Weeks With Concurrent Herceptin for Subjects With HER-2/Neu Positive Disease, Phase II

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00407888
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:27.218108+00:00
Published At: 2017-08-31T00:00:00+00:00
Record Updated At: 2017-08-31
Results Posted At: 2017-08-31
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Estrogen Receptor-positive Breast Cancer", "HER2-positive Breast Cancer", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2017-08-31"
protocolSection.identificationModule.nctId: "NCT00407888"
protocolSection.identificationModule.officialTitle: "Adjuvant Therapy for High-Risk Localized Breast Cancer Using Weekly Adriamycin + Daily Oral Cytoxan With Continuous G-CSF Support for 12 Weeks Followed by Weekly Abraxane\u2122 for 12 Weeks With Concurrent Herceptin for Subjects With HER-2/Neu Positive Disease, Phase II"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2017-08-31"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.